Spyre Therapeutics (SYRE) Shares Outstanding (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Shares Outstanding (Entity) data on file, last reported at $78.8 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 30.8% year-over-year to $78.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $78.8 million (up 30.8% YoY) and the FY2025 annual result came in at $64.1 million, up 36.21% from the prior year.
• Shares Outstanding (Entity) climbed to $78.8 million in Q1 2026, from $64.1 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $78.8 million in Q1 2026 to a low of $2.6 million in Q1 2022.
• A 5-year average of $31.8 million and a median of $36.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) retreated 1.47% — and 2024, when it soared 1467.34%.
• Tracing SYRE's Shares Outstanding (Entity) over 5 years: stood at $3.4 million in 2022, then surged by 104.59% to $6.9 million in 2023, then jumped by 581.85% to $47.0 million in 2024, then soared by 36.21% to $64.1 million in 2025, then advanced by 23.08% to $78.8 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $78.8 million (Q1 2026), $64.1 million (Q4 2025), and $60.5 million (Q3 2025), per Business Quant data.